Discover the latest drugs and treatment options in the Influenza Pipeline. Dive into DelveInsight's comprehensive report today! @ Influenza Pipeline Outlook In April 2025, Eurofarma Laboratories S.A ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Scientists at the University of California, Riverside, have discovered how adult stem cells retain their regenerative power.

Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, ...

"The cells dedifferentiate back into a type of regenerative stem cell after injury, and those stem cells eventually recover the intestine and turn back to normal cells." Finding the switch ...

The US Food and Drug Administration (FDA) approved the first CAR T-cell therapies in 2017 for diffuse large B-cell lymphoma and acute lymphoblastic leukemia in pediatric and young adult patients.

Pacific Peoples' Experiences of Cancer and Its Treatment in Aotearoa New Zealand Through Talanoa: A Qualitative Study of Samoan and Tongan Participants Healthy volunteers were recruited and underwent ...